you are viewing a single comment's thread.
1. efficacy of phase 1 trial data---small sample but results can't be ignored2. patent protection on ICT-107 their lead candidate3. licensing agreements in place to further develop pipeline4. strong cash position and low burn rate ----see the recent sec filing to verify this5. manufacturing process allows them to produce their compound at a relatively low cost per dose, which will translate to higher profit margins compared to peers